Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of “Buy” by Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned an average recommendation of “Buy” from the nine analysts that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $15.97.

VYGR has been the topic of a number of research analyst reports. Cantor Fitzgerald began coverage on shares of Voyager Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $5.73 price target on the stock. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Leerink Partners began coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Citigroup assumed coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $5.19 on Friday. The firm has a market cap of $283.53 million, a P/E ratio of 7.31 and a beta of 0.93. The stock’s 50 day moving average is $5.99 and its 200 day moving average is $6.75. Voyager Therapeutics has a one year low of $5.03 and a one year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the previous year, the company earned ($0.59) EPS. Equities analysts anticipate that Voyager Therapeutics will post -0.89 earnings per share for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 10,778 shares of company stock valued at $58,548 over the last ninety days. 4.53% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Armistice Capital LLC raised its holdings in shares of Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after acquiring an additional 528,000 shares during the last quarter. Great Point Partners LLC purchased a new stake in shares of Voyager Therapeutics in the second quarter worth approximately $12,668,000. Geode Capital Management LLC lifted its holdings in shares of Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after purchasing an additional 6,740 shares in the last quarter. Erste Asset Management GmbH purchased a new position in shares of Voyager Therapeutics during the third quarter valued at approximately $6,192,000. Finally, American Century Companies Inc. grew its holdings in Voyager Therapeutics by 32.4% during the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after buying an additional 249,659 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.